A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria: * Adult patients; \>/= 18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 * Relapsed or refractory multiple myeloma for which no effective standard therapy exists * One of the prior therapies must have included a proteosome inhibitor or an immunomodulatory drug * Measurable disease as defined by protocol Exclusion Criteria: * Prior use of monoclonal antibody within 4 weeks before Cycle 1, Day 1 * Treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1 * Toxicities from any previous treatment must be resolved prior to Cycle 1, Day 1, except for neuropathy * Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1 * Prior allogeneic stem cell transplant * History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins) * Grade \> 1 peripheral neuropathy * Active infection at screening or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to Cycle 1, Day 1 * Positive for hepatitis B, hepatitis C or HIV infection * Pregnant or lactating women or women who intend to become pregnant within the period of time of this study